secwatch.observer — SEC 8-K summary
======================================

Issuer:     PFIZER INC (PFE)
CIK:        0000078003
Form:       8-K
Filed at:   2022-11-01T23:59:59+00:00
Accession:  0000078003-22-000098
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pfizer Q3 revenue $22.6B (-6% YoY); Adj. EPS $1.78 (+40%); raises FY2022 guidance
--------------------------------------------------------------------------------

- Reported diluted EPS $1.51 (+6%); Adjusted diluted EPS $1.78 (+40%) YoY.
- Paxlovid contributed $7.5B in Q3; Comirnaty revenue guidance raised to ~$34B for 2022.
- FY2022 revenue guidance raised to $99.5-102.0B; Adj. EPS guidance raised to $6.40-6.50.
- Completed Biohaven ($12.8B) and GBT ($5.6B) acquisitions early Q4 2022.
- Positive Phase 3 readouts for RSV vaccine, Prevnar 20 in pediatrics, and Talzenna/Xtandi combo.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/78003/000007800322000098/0000078003-22-000098-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/78003/000007800322000098/pfe-20221101.htm
  HTML page:      https://secwatch.observer/filing/0000078003-22-000098

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer